9/19 Vasculotide, An Angiopoietin 1 Mimetic, Protects Vascular Barrier Function In Acute Lung Injury
September 1, 2018
Events and Seminars
A Seminar by Dr. Paul Van Slyke, CSO for Vasomume Therapeutics, will be held on Sept 19.
Wednesday, September 19th, 2018, 13:30-14:30
|Venue||Biken Hall, 1st floor, Main Building, RIMD|
Paul Van Slyke, Ph.D.
Vasculotide, An Angiopoietin 1 Mimetic, Protects Vascular Barrier Function In Acute Lung Injury
Tie2 is a receptor tyrosine kinase expressed primarily on endothelial cells throughout the body. Constitutive activation of this receptor, through engagement with its cognate ligand Angiopoietin 1, is critical to the maintenance of normal vascular barrier function. Dysregulation of the Tie2 pathway has been widely implicated in several critical care indications marked by vascular leak. As such, modulation of the Tie2 pathway has become a major target of interest for the pharmaceutical industry.
Vasomune Therapeutics, a private biotechnology company based in Toronto, Canada has recently entered into a Co-Development Agreement with AnGes, Inc. (Osaka) to develop Vasculotide, an Angiopoietin 1 mimetic, for the treatment of acute respiratory distress syndrome (ARDS). The concept for Vasculotide as well as preclinical proof-of-concept data derived from three different models of ARDS will be discussed.
|Host||Prof. Nobuyuki Takakura (Dept. Signal Transduction)|
|Support||Innovators’ Club, Osaka University|
*The seminar will be conducted in English.
**The seminar has been certified as a newly appointed researchers training program as part of the
Osaka University Faculty Development.
Contact: Office for Research Promotion, Research Institute for Microbial Diseases, Osaka University
E-mail: biken-pr*biken.osaka-u.ac.jp (Please replace * with @)